Monitoring the safety of influenza A (H1N1) vaccine using web-based intensive monitoring

Vaccine

Volumn 29, Issue 10, 2011, Pages 1941-1947

  Härmark, Linda ^a,b   van Hunsel, Florence ^a,b   Hak, Eelko ^b,c   van Grootheest, Kees ^a,b  

^a NETHERLANDS PHARMACOVIGILANCE CENTRE LAREB   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Adverse events following immunisation; Focetria; Influenza vaccine; Intensive monitoring; Safety

Indexed keywords

INFLUENZA VACCINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; AGITATION; ARTHRALGIA; ARTICLE; CARDIOVASCULAR DISEASE; CHILD; COHORT ANALYSIS; COMORBIDITY; COUGHING; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPHONIA; DYSPNEA; ERUCTATION; FATIGUE; FEMALE; FEVER; FLANK PAIN; HEADACHE; HEART PALPITATION; HERPES SIMPLEX; HUMAN; INFANT; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INJECTION SITE WARMTH; LIMB PAIN; LUNG DISEASE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MOUTH PAIN; MUSCLE WEAKNESS; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PANDEMIC; PERIPHERAL EDEMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RHINOPHARYNGITIS; RHINORRHEA; RISK FACTOR; SCHOOL CHILD; SIDE EFFECT; VACCINATION; WEB BROWSER;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; COHORT STUDIES; DRUG TOXICITY; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INTERNET; MALE; MIDDLE AGED; PREGNANCY; PROSPECTIVE STUDIES; VACCINATION;

EID: 79951723177     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.123     Document Type: Article

References (23)

1. Outbreak of swine-origin influenza A (H1N1) virus infection - Mexico, March-April 2009. MMWR. Morb. Mortal. Wkly. Rep. 2009;58(17):467-70.
2. New influenzaA (H1N1) virus: global epidemiological situation, June 2009. Wkly. Epidemiol. Rec. 2009, 84(25):249-257.
3. European Medicines Agency pandemic influenza (H1N1) website. (version date: 2010, access date: European Medicines Agency.
4. Vaccine safety: informing the misinformed. Lancet Infect Dis 2009, 9(12):719.
5. Huang W.T., Chuang J.H., Kuo S.H. Monitoring the safety of pandemic H1N1 vaccine. Lancet 2010, 375(9721):1164.
6. Destefano F., Tokars J. H1N1 vaccine safety monitoring: beyond background rates. Lancet 2010, 375(9721):1146-1147.
7. Vaccine safety and adverse events following immunization. WHO 2010, http://www.who.int/immunization_monitoring/routine/immunization_adverse/en/index.html.
8. Harmark L., van Grootheest A.C. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol 2008, 64(8):743-752.
9. Härmark L., Kabel J.S., van Puijenbroek E.P., van Grootheest A.C. Web-based intensive monitoring, a new patient based tool for early signal detection. Drug Safety 2006, 29(10):911-1010. [Abstract].
10. van Grootheest A.C., Härmark L., Oosterhuis I., van Puijenbroek E.P. Lareb intensive monitoring, a web based system for monitoring ADRs in the postmarketing phase. Pharmacoepidemiol Drug Safety 2007, 16:S252-S253. [Abstract].
11. The Health Council of theNetherlands. Vaccinatie tegen pandemische influenza A/H1N1 2009: doelgroepen en prioritering. http://www.gezondheidsraad.nl/sites/default/files/samenvatting%2520200910_0.pdf.
12. The Health Council of theNetherlands. Aanvulling advies vaccinatie influenza A/H1N1 2009. http://www.gezondheidsraad.nl/sites/default/files/persbericht%2520200912.pdf.
13. Hak E., Buskens E., van Essen G.A., de Bakker D.H., Grobbee D.E., Tacken M.A., et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. Arch Intern Med 2005, 165(3):274-280.
14. SmPC Focetria®. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000710/WC500023749.pdf.
15. Council for International Organisations of Medical Sciences International reporting of adverse drug reactions. CIOMS working group report 1987, World Health Organisation, Geneva.
16. The council of the european communities. Regulation (EEC) No 2309/93. http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-1/reg_1993_2309/reg_1993_2309_en.pdf.
17. http://www.surveymonkey.com/.
18. MedDRA and MSSO. http://www.meddramsso.com/MSSOWeb/index.htm.
19. Tacken M. Mulder J, Visscher S, Tiersma W, Donkers J, Verheij R. et al. Monitoring vaccination rate Dutch National Influenza Prevention Program 2009. http://www.nivel.nl/pdf/LINH%2520griepmonitoring%25202009%2520rapport.pdf.
20. de Langen J., van Hunsel F., Passier A., de Jong-van den Berg L., van Grootheest K. Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf 2008, 31(6):515-524.
21. Centraal Bureau voor de Statistiek. Mediaproducten steed meer via internet.
22. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(25):2424-2435.
23. Dielemann J, Sturkenboom M, Hviid A, Kilpi T, Storsaeter J, Mannino S et al. European wide study on the association between Guillain-Barré syndrome and new Influenza A (H1N1) vaccination. [Poster] http://www.ecdc.europa.eu/en/activities/diseaseprogrammes/Eurovaccine/Documents/0912-eurovaccine-ID21-Dieleman-Guillain-Barre.pdf.